Which commonly prescribed medication may exacerbate a complication associated with massive transfusion?

The correct answer relates to the potential for calcium channel blockers, such as diltiazem, to exacerbate complications associated with massive transfusion. Massive transfusion can lead to coagulopathy due to dilution of clotting factors and platelets, as well as potential hypocalcemia from citrate used in blood products. Calcium plays a vital role in platelet function and coagulation cascade.

Diltiazem, being a calcium channel blocker, can impact calcium levels and affect the body’s ability to properly manage coagulation during massive transfusion. While other medications listed may contribute to different effects in the overall management of a patient, it is the mechanism of action of diltiazem that makes it more likely to have a direct exacerbating influence on transfusion-related complications linked to calcium management.

Understanding the pharmacology and physiological effects of these medications in the context of massive transfusion is essential for trauma nursing practice, as it directly relates to patient outcomes and the effective management of hemorrhagic shock.